Pertussis (Tdap) Vaccination in Pregnancy

Phase 4

Completed

• Conditions: Pertussis; Pregnancy
• Interventions: Biological: Pertussis vaccine

• Registration Number: NCT01698346
• Lead Sponsor: Universiteit Antwerpen

Brief Summary

Despite good vaccination coverage, included in national immunization programs in developed countries, the number of reported pertussis cases is rising, also in very young infants. Current immunization strategies fail to protect infants too young to be immunized with the licensed vaccine. Different strategies are possible to close the gap of susceptibility between the loss of maternal antibodies and protection by vaccination. The main aim of the present study is to measure the influence of an adult pertussis booster in pregnant women, on the titer and duration of maternal antibodies in their infants. Early humoral immunity will be assessed and the influence on vaccine response of the infant measured. The present study offers the opportunity to have new insights in neonatal immunological mechanisms against pertussis and a better understanding in strategies to protect infants against pertussis.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02
• Study First Submitted: 2012-09-21
• Study First Submitted QC: 2012-09-28
• Study First Posted: 2012-10-03
• Primary Completion: 2015-12
• Study Completion: 2016-12
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-22
• Last Update Posted: 2019-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 99

Inclusion Criteria

• Women aged 18-35 years
• Willing to be immunized during pregnancy OR
• Received already a pertussis vaccination during pregnancy, as advised by gynaecologist or general practitioner.
• Age matched controls will be identified in the same time period in the recruiting hospital.
• Availability for follow-up visits and phone call access through 16 months following delivery
• Willing to have infant immunized with hexavalent vaccine at 8.12 and 16 weeks and 15 months of age (= normal Belgian schedule) with pediatrician, the general practitioner or at the Centre for the Evaluation of Vaccination.
• In the 18th-32nd week of a pregnancy at low risk for complications as determined by the obstetrician

Exclusion Criteria

Women:

• Serious underlying medical condition
• History of a febrile illness (>= 38° Celsius) within the past 72 hours before injection
• Previous severe reaction to any vaccine
• Receipt of tetanus-diphtheria toxoid immunization within the past 1 month
• Receipt of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap) immunization in the last 10 years
• Receipt of a vaccine, blood product (excluding Rhogam) or experimental medicine within the 4 weeks prior to injection through 4 weeks following injection
• Receipt of or plans to receive influenza vaccine within the 4weeks prior to or following injection. One month interval should be respected in order to evaluate eventual Adverse events following one of both vaccines (fever, local symptoms).
• High risk for serious obstetrical complication
• Anything in the opinion of the investigator that would put the participant at risk.

Exclusion criteria for the offspring:

• Serious underlying medical condition
• No signed informed consent by both parents
• Severe reactions to any vaccine
• Anything in the opinion of the investigator that would put the participant at risk.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)	Pertussis vaccine	50 pregnant women vaccinated with pertussis vaccine

Primary Outcome Measures

Name	Time	Method
Does vaccination of pregnant women with a combined vaccine Tetanus, diphtheria and acellular pertussis (Tdap), induce sufficiently high maternal antibody concentration in the newborns infants to possibly protect them until their own vaccination starts	16 months	1. What are the concentrations of IgG against Pertussis Toxin (anti-PT), Filamentous Haemagglutinin (anti-FHA), Fimbriae (anti-Fim) and pertactin (anti-PRN): 1. in women during pregnancy and at delivery after vaccination with TdaP; 2. in children at birth (cord), before starting vaccination (week 8), one month after primary course of three doses (week 20) and before and after the fourth pertussis vaccine dose (at month 15 and 16); 2. What are the concentrations of anti-tetanus and anti-diphtheria IgG antibodies at all mentioned time points, to evaluate interference when administering several antigens and to evaluate the influence of maternal antibodies on vaccine response to tetanus and diphtheria in infants

Secondary Outcome Measures

Name	Time	Method
Vaccine associated (Severe) Adverse Events ((S)AE) in pregnant women and children during the study time	16 months	Vaccine associated (Severe) Adverse Events ((S)AE) in pregnant women and children during the study time
Infant growth measurement at all time points	16 months	Infant growth measurement at all time points
Assessment of pneumococcal immune response in infants whose mothers received Tdap vaccination during pregnancy	12 months	The present trial on pertussis vaccination during pregnancy, offers the opportunity to add evidence for a possible blunting effect of infant immune responses to pneumococcal infant vaccination after maternal Tdap vaccination. Pneumococcal antibodies will be measured in serum samples taken from infants after a primary series of 2 pneumococcal vaccine doses (2 and 4 months of age) and after a third vaccine dose (at 12 months of age). Infants are born from either vaccinated or unvaccinated mothers.

Trial Locations

Locations (2)

Centre for the Evaluation of Vaccination; 🇧🇪 Antwerp, Belgium

National Institute of Hygien and Epidemiology; 🇻🇳 Hanoi, Vietnam